Takeda penned a potentially billion-dollar deal with Anima Biotech to work on mRNA translation modulators for neurological diseases. The Japanese pharma also launched a digital health incubator in Shanghai. Fellow Japanese drugmaker Daiichi Sankyo has ushered its mRNA COVID-19 vaccine into a phase 1/2 trial for initial safety and immunogenicity analysis. And more.